ReviewDermatology and therapy2026
The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa-A Narrative Review.
Review in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory Manifestations, Therapeutic Interventions, and Cancer Risk in Psoriasis: Current Epidemiological and Mechanistic Evidence.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammatory skin diseases (CISDs) such as psoriasis (PsO), atopic dermatitis (AD), and hidradenitis suppurativa (HS) involve both cutaneous and systemic immune dysregulation, whereas commonly used scores rely largely on subjective clinical features and insufficiently reflect underlying inflammatory activity or cardiovascular risk. This review summarizes evidence across three biomarker domains: tissue-level pathways (the Fas/FasL and interleukin (IL)-21/IL-21R), circulating inflammatory mediators, and hematology-derived indices (the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), pan-immune-inflammation value (PIV), derived neutrophil-to-lymphocyte ratio (d-NLR), systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), and aggregate index of systemic inflammation (AISI)) in relation to disease activity, therapeutic response, and cardiometabolic burden. A targeted literature search was performed in PubMed/MEDLINE, Scopus, and the Cochrane Library (January 2000 to November 2025), supplemented by artificial intelligence (AI)-assisted retrieval, manual screening of reference lists, and citation tracking. Studies providing patient-derived clinical or translational data were included and summarized in structured comparative tables. The findings indicate that dysregulated Fas/FasL signaling contributes to keratinocyte apoptosis resistance and chronic epidermal inflammation in PsO and AD, with limited data in HS. IL-21 is elevated in PsO and AD, correlating with clinical severity and epidermal hyperplasia, whereas its role in HS remains unexplored despite the strong Th17 and B-cell signature of the disease. Complete blood count-derived indices demonstrate associations with systemic inflammation and increased cardiometabolic risk, particularly in PsO and HS, yet diagnostic performance varies and methodological standardization is lacking. Taken together, these biomarkers provide insights into local and systemic aspects of disease biology but are not yet validated for clinical use. Integrating tissue-specific mediators, soluble biomarkers, and hematologic indices into multimodal panels may ultimately strengthen precision monitoring of disease activity, treatment response, and cardiovascular risk in CISDs. Prospective, multicenter studies are needed to establish clinically actionable, biomarker-driven strategies that enable more mechanism informed and personalized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.